Faculty Of Medicine 2
51. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
52. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
53. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
54. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
55. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
56. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
57. Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan
58. Barriers to COVID-19 vaccination among medical students in Kazakhstan: development, validation, and use of a new COVID-19 Vaccine Hesitancy Scale
59. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
60. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
61. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
62. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
63. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
64. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
65. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
66. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
67. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
68. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
69. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
70. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
71. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
72. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
73. Management of anaphylaxis due to COVID-19 vaccines in the elderly
74. Management of anaphylaxis due to COVID-19 vaccines in the elderly
75. Management of anaphylaxis due to COVID-19 vaccines in the elderly
76. Management of anaphylaxis due to COVID-19 vaccines in the elderly
77. Management of anaphylaxis due to COVID-19 vaccines in the elderly
78. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
79. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
80. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
81. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
82. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
83. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
84. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
85. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
86. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
87. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
88. Integrative bioinformatics and artificial intelligence analyses of transcriptomics data identified genes associated with major depressive disorders including NRG1
89. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
90. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
91. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
92. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
93. Methodology and implementation of the WHO European Childhood Obesity Surveillance Initiative (COSI)
94. Methodology and implementation of the WHO European Childhood Obesity Surveillance Initiative (COSI)
95. Methodology and implementation of the WHO European Childhood Obesity Surveillance Initiative (COSI)
96. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
97. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
98. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
99. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020
100. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020
1 2 3 4 14